Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Multiple Sclerosis

    California

    Search
    Multiple Sclerosis
    California
    Show Map
    Map View
    California
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      64 Multiple Sclerosis Trials near California

      Power is an online platform that helps thousands of Multiple Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      N-acetyl Cysteine for Multiple Sclerosis

      San Francisco, California
      This trial tests if N-acetyl cysteine (NAC) can help people with progressive multiple sclerosis by protecting brain cells and reducing inflammation. Participants will be divided into two groups, with one group taking NAC. N-acetyl cysteine (NAC) has been studied for its potential benefits in various conditions, including multiple sclerosis, cannabis use disorder, and chronic obstructive pulmonary disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:40 - 70

      Key Eligibility Criteria

      Disqualifiers:MS Relapses, Pregnancy, Bleeding Disorders, Others
      Must Be Taking:Disease-modifying Treatments, Dalfampridine

      98 Participants Needed

      Bazedoxifene Acetate for Multiple Sclerosis

      San Francisco, California
      The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigational new drug research study.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:40 - 65
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Cancer, Pregnancy, Thromboembolism, Cardiac Block, Others
      Must Not Be Taking:Clemastine, Duavee, Tamoxifen, Others

      62 Participants Needed

      Ocrelizumab Formulations for Multiple Sclerosis

      Carlsbad, California
      The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Cancer, Immunocompromised, Cardiovascular, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppressants

      182 Participants Needed

      Obexelimab for Multiple Sclerosis

      West Hollywood, California
      This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Primary Progressive MS, Neuromyelitis Optica, Others

      93 Participants Needed

      CAR T-Cell Therapy for Multiple Sclerosis

      Palo Alto, California
      A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Stroke, Others
      Must Be Taking:Anti-CD20 MAb

      120 Participants Needed

      BIIB091 for Relapsing Multiple Sclerosis

      Orange, California
      In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, Recent MS Relapse, HIV, Others
      Must Not Be Taking:Fumarates, BTK Inhibitors

      275 Participants Needed

      Fenebrutinib for Multiple Sclerosis

      Las Vegas, Nevada
      This trial is testing fenebrutinib, a medication, to see its effects on the brain in people with relapsing multiple sclerosis (RMS). Researchers will use MRI scans to observe any changes. They will also check if the drug is safe and how it is processed by the body. Participants will either receive fenebrutinib or a non-active substance.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Cancer, Neurological Disorders, Cardiovascular, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppressants

      109 Participants Needed

      CAR T Cell Therapy for Multiple Sclerosis

      San Francisco, California
      The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:25 - 70

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B/C, Cardiac Disease, Others
      Must Not Be Taking:Anticoagulants, Mitoxantrone, Cladribine, Alemtuzumab

      10 Participants Needed

      CAR T-cell Therapy for Multiple Sclerosis

      Palo Alto, California
      A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets, Anti-CD20

      12 Participants Needed

      Ketamine for MS Fatigue

      Berkeley, California
      The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue. The investigator proposes a prospective, crossover, randomized, placebo-controlled study to assess the efficacy and safety of low, single dose Ketamine, to assess its efficacy and safety in patients with MS-related fatigue.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Sleep Apnea, Hypertension, Liver Disease, Others
      Must Not Be Taking:Ketamine Interactors

      20 Participants Needed

      Metformin for Progressive Multiple Sclerosis

      Los Angeles, California
      This trial is testing metformin, a diabetes medication, to see if it can help adults aged 30-65 with progressive multiple sclerosis. The goal is to find out if metformin can reduce inflammation and protect nerve cells, potentially slowing down the disease.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:30 - 65

      Key Eligibility Criteria

      Disqualifiers:Renal Dysfunction, Hepatic Dysfunction, Others
      Must Not Be Taking:Glucocorticoids, Metformin, Others

      44 Participants Needed

      Whole-Body PET Scans for Multiple Sclerosis

      Ladera Ranch, California
      To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Age:25 - 55

      Key Eligibility Criteria

      Disqualifiers:Neuropsychiatric Illness, Diabetes, Cancer, Others

      20 Participants Needed

      Nivolumab for Cancer

      Sacramento, California
      This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
      Must Not Be Taking:Anticancer Investigational Agents

      300 Participants Needed

      P-CD19CD20-ALLO1 for Multiple Sclerosis

      La Jolla, California
      This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, PML, HLH/MAS, Others
      Must Not Be Taking:Immunosuppressants, Immunomodulators

      60 Participants Needed

      RO7121932 for Multiple Sclerosis

      Stanford, California
      This trial is testing a new drug called RO7121932 to see if it is safe and well-tolerated. The drug is being given to people with multiple sclerosis (MS) in different ways, either through a vein or under the skin. The goal is to find out if the drug can help treat MS without causing harmful side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Active Infections, Cancer History, Neurological Disorders, Others
      Must Not Be Taking:MS Treatments, Anti-CD20 Therapies

      129 Participants Needed

      Mobile App for Depression in Multiple Sclerosis

      San Francisco, California
      The researchers want to find out if an electronic application called MS CATCH can enhance patients' and doctors' experiences during and in between clinical visits. MS CATCH is a smartphone-based tool which allows patients to enter their mood related symptoms at regular intervals, which is then available to their Neurologist in their electronic medical record. The neurologist is also able to view additional information from their medical record, and receives alerts for changes reported by the patient that raise concern for the patient's mental health.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Psychotic Disorders, Substance Abuse, Others

      100 Participants Needed

      MS FIT App for Multiple Sclerosis

      San Francisco, California
      This trial tests the MS FIT app, which helps MS patients track falls, view health data, and get fall prevention tips. It targets MS patients because they often experience falls that affect their daily lives. The app uses data from health records, wearables, and surveys to monitor falls and provide personalized advice.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Cognitive Impairment, Visual Impairment, Others

      100 Participants Needed

      MSCopilot® App for Multiple Sclerosis

      San Diego, California
      This trial is testing MSCopilot® Detect, a smartphone app that helps people with Multiple Sclerosis (MS) monitor their condition from home. The app aims to make it easier to track disease progression and improve patient care. It involves 314 MS patients from several countries who will use the app to complete periodic questionnaires and tests. MSCopilot is a software medical device designed for the self-assessment of people with Multiple Sclerosis (PwMS), validated against traditional tests.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:30 - 65

      Key Eligibility Criteria

      Disqualifiers:Medically Unstable, Visual Acuity, Pregnancy, Others

      336 Participants Needed

      Wearables + Physical Therapy for Overactive Bladder in Multiple Sclerosis

      San Francisco, California
      The goal is to investigate the feasibility and effects of adding "wearables for the bladder" devices to conventional pelvic floor physical therapy (PFPT) to bladder function, in people with multiple sclerosis (MS).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Recent Relapse, Pregnancy, Others

      20 Participants Needed

      Telehealth vs In-Clinic Care for Multiple Sclerosis

      San Francisco, California
      The current standard of outpatient MS care depends on in-clinic visits, but MS patients face many barriers to accessing this care. These barriers include those resulting from the disease itself, such as physical limitations, driving restrictions and financial limitations, and they are further compounded by an overall shortage of neurologists. Furthermore, MS care has a significant economic impact, with the estimated indirect and direct costs for treating MS in the US estimated to be \> $85.4 billion. Therefore, there is a need to improve access to and reduce cost of MS care, and telehealth is a potential solution. The VIRTUAL-MS study has been designed to evaluate the impact of telehealth care on MS clinical outcomes, costs, and satisfaction compared to in-person care. Additionally, the study aims to evaluate facilitators and barriers to telehealth use to inform widespread implementation.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Neutropenia, Wound Care, Others

      120 Participants Needed

      Why Other Patients Applied

      "I have been losing mobility in the past 3 years very rapidly. I have tried physical therapy, but it didn't really show results. I'll admit that I am not very self-motivated, so I can use some structure. I use to be extremely active and now I am like a wet rag. So I am hoping that participating in a research trial will be of help to me."

      AK
      Multiple Sclerosis PatientAge: 75

      "I've been using natural supplements and would like to find something more effective. My former PCP was hesitant to prescribe modafanil. I'm interested in learning about all options available to me—including the drugs currently under research investigation."

      GK
      Multiple Sclerosis PatientAge: 50

      "I've tried 2 MS drugs but I am getting worse. I am having trouble walking long distances or for more than 30 minutes. I need to find a new medication. My doctor and I discussed some of the options in trials and I'm ready to dive in to learn more."

      OL
      Multiple Sclerosis PatientAge: 57

      "I am 42 yrs old with 2 little kids, work as a nurse, tried several drugs, most made me feel awful. I want my quality of life. I don’t want to have to take something daily/monthly. I don’t like the side effects of many drugs. I'm excited to be considered as a candidate for one of these trials."

      KT
      Multiple Sclerosis PatientAge: 44

      "I've been battling multiple sclerosis for 28 years. I've tried three medications. I keep my dosing stable, but I'm just tired of managing. I want to take control of my situation."

      KE
      Multiple Sclerosis PatientAge: 43
      Match to a Multiple Sclerosis Trial

      Early Aggressive vs Traditional Therapy for Multiple Sclerosis

      Carmichael, California
      FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breast-feeding, Chemotherapy, Others
      Must Not Be Taking:Rituximab, Ocrelizumab, Teriflunomide, Others

      900 Participants Needed

      Fasting Mimicking Diet for Multiple Sclerosis

      Los Angeles, California
      In the proposed study, investigators will assess the safety and feasibility of cycles of a fasting mimicking diet (FMD) and its effect on Multiple Sclerosis Quality of Life (MSQOL) in relapsing MS (RMS) patients treated with standard disease modifying therapies (FMDMS). To test the primary hypothesis, investigators will compare the composite quality of life score in terms of improvement in disability, fatigue, and cognitive function with the fasting protocol, as compared to a Mediterranean diet (control) group alone. Further, investigators hypothesize that the effects will remain for at least 6-months after the last FMD cycle. The Mediterranean diet (MD) has been chosen as the control diet to minimize baseline dietary differences among patients. It has been trialed for feasibility in Multiple Sclerosis patients and used in a previous human FMD trial for MS patients where a FMD followed by MD was shown to have positive effects on people with MS.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Malignancy, Pregnancy, Diabetes, Others
      Must Not Be Taking:Glucocorticoids

      50 Participants Needed

      Ofatumumab for Multiple Sclerosis

      Fullerton, California
      Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      562 Participants Needed

      IMU-838 for Progressive Multiple Sclerosis

      Torrance, California
      This trial is testing a new medication called IMU-838 to help adults with Progressive Multiple Sclerosis. The medication aims to reduce inflammation and slow down the worsening of the disease. The study will check if the medication is safe and effective over a long period.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      450 Participants Needed

      Brain-Computer Interface Device for Severe Neurological Disorders

      San Francisco, California
      This trial is testing a method that uses sensors on the brain to help people with severe neurological disorders control devices and speak. The sensors pick up brain signals and translate them into actions or speech. This could help those who struggle with movement and communication due to their condition.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Dementia, Active Depression, Substance Abuse, Others

      3 Participants Needed

      CC-97540 for Multiple Sclerosis

      Irvine, California
      This trial is testing a new drug called CC-97540 to see if it is safe and effective for people with relapsing or progressive multiple sclerosis. The goal is to find out if it can help manage symptoms or slow down the disease.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Myositis, Stroke, CIDP, Others
      Must Be Taking:High-efficacy DMTs, Immunosuppressants

      120 Participants Needed

      Exercise for Multiple Sclerosis

      La Jolla, California
      This multi-center, randomized controlled feasibility trial will assess a 20-week home-based exercise intervention in youth with Multiple Sclerosis (MS). The goal is to determine the feasibility of conducting a larger, definitive trial on exercise training as a non-pharmacological approach to improve disease outcomes in this population. Participants will be randomized to either an Exercise Training group or a Mobility and Flexibility Training group. The investigators will evaluate differences between the two groups in physical activity levels, mediators of physical activity, and psychosocial outcomes. Assessments, including clinical exams, brain MRI, eye tracking, cognitive testing, blood draws, and questionnaires, will occur at baseline and after 20 weeks. Accelerometry will be done at baseline, 10 weeks, and 20 weeks to track physical activity. The primary objectives are to assess the feasibility of recruiting, retaining, and randomizing youth with MS and to evaluate adherence to the exercise intervention and coaching sessions. Exploratory objectives include examining changes in depressive symptoms, cognitive function, blood biomarkers (BDNF and irisin), brain volume, and fitness levels in response to the intervention. Approximately 40 participants will be enrolled from four sites in Canada and the United States. Primary outcomes include feasibility, acceptability, and fidelity measures. Exploratory outcomes include blood biomarkers, brain MRI, cognitive testing, and other neuropsychological measures.

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:11 - 25

      Key Eligibility Criteria

      Disqualifiers:Non-specific White Matter, Motor Disability, Cardiac Risk, Others

      40 Participants Needed

      IDP-023 + Ocrelizumab for Multiple Sclerosis

      San Francisco, California
      This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Relapsing MS, CNS Tumor, HIV, Others
      Must Be Taking:Ocrelizumab

      34 Participants Needed

      RP2/RP3 + Atezolizumab + Bevacizumab for Colorectal Cancer

      Los Angeles, California
      This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hepatitis, HIV, CNS Metastases, Others
      Must Not Be Taking:Antivirals, Immunosuppressants

      4 Participants Needed

      ATP128 + VSV-GP128 + BI 754091 for Colorectal Cancer

      Los Angeles, California
      This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091. ATP128 is a self-adjuvanted chimeric recombinant protein vaccine being developed in combination with programmed cell death 1 (PD-1) blockade for the treatment of microsatellite stable (MSS) patients not responding to PD-1 blockade. The PD-1 inhibitor being tested with ATP128 is the BI 754091 (Ezabenlimab) compound which belongs to the human immunoglobulin G4 (IgG4) subclass of antibodies. VSV-GP is a recombinant chimeric vesicular stomatitis virus (VSV, Indiana strain Rhabdoviridae) which carries the envelope glycoprotein (GP) of the visceral non neurotropic WE-HPI strain of the Lymphocytic choriomeningitis virus (LCMV, Arenaviridae) instead of the native VSV glycoprotein (G) and is developed as integral part of the prime-boost regimen together with ATP128. The Sponsor plans to enrol 96 patients with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations: * Cohort 1a: 6 patients with stage IV colorectal cancer (CRC) having failed standard of care (SoC) therapies * Cohorts 1b, 2a, 2c: 30 patients with stage IV microsatellite stable/mismatch repair-proficient (MSS/MMRp) CRC being in stable disease (SD) or partial response (PR) after first line of SoC (4-6 months duration at minimum) * Cohorts 2b, 4b: 30 patients with stage IV MSS/MMRp liver-limited disease Patients eligible for this study will be enrolled in one of the 8 cohorts depending on their disease: * Patients in Cohort 1a will receive ATP128 as single agent * Patients in Cohorts 1b, 2a, 2b, 2c will receive ATP128 in combination with BI 754091 * Patients in Cohorts 3, 4a, 4b will receive ATP128 and VSV-GP128 in combination with BI 754091
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Active Infection, CNS Metastasis, Others
      Must Not Be Taking:Checkpoint Inhibitors, Immunotherapy

      96 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Pathology Clinical Trials

      207 Clinical Trials near Belzoni, MS

      Top Clinical Trials near Butler, PA

      Top Clinical Trials near Scottsdale, AZ

      Top Clinical Trials near Brightwaters, NY

      Top Clinical Trials near Fullerton, CA

      Top Clinical Trials near Elizabeth City, NC

      Top Clinical Trials near Hobart, IN

      Top Autism Clinical Trials near San Diego, CA

      Top Systemic Lupus Erythematosus Clinical Trials

      Top Clinical Trials near Elkton Md, MD

      28 Prostate Cancer Trials near High Point, NC

      By Trial

      Salbutamol for Athletic Performance

      MRI + iEEG for Epilepsy

      Single-Dose Antibiotics for Preventing Surgical Site Infections

      Clinical Decision Framework for Chronic Conditions in Older Adults

      Everolimus for Tracheal Stenosis

      CAR-T Cell Therapy for Relapsing Breast Cancer

      TENS Device and Integrative Health Techniques for Back Pain

      Palbociclib + INCMGA00012 for Liposarcoma

      Tailored Therapy for Endometrial Cancer

      CAR T-Cell Therapy for Leukemia and Lymphoma

      MISSION-CJ Program for Substance Abuse and Mental Health Issues in Homeless Veterans

      Pembrolizumab for Pediatric Cancer

      Frequently Asked Questions

      How much do Multiple Sclerosis clinical trials in California pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Multiple Sclerosis clinical trials in California work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple Sclerosis trials in California 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in California for Multiple Sclerosis is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in California several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Multiple Sclerosis medical study in California?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Multiple Sclerosis clinical trials in California?

      Most recently, we added Ocrelizumab Formulations for Multiple Sclerosis, P-CD19CD20-ALLO1 for Multiple Sclerosis and RE104 for Adjustment Disorder to the Power online platform.

      What do the "Power Preferred" and "SuperSite" badges mean?

      We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

      Which clinics have received Power Preferred and SuperSite awards recruiting for Multiple Sclerosis trials in California?

      The Multiple Sclerosis clinics in California currently recognized as SuperSites are: Regina Berkovich, MD, PhD Site Number : 8400005 in West Hollywood, California

      Can MS go into remission?

      Yes. In relapsing-remitting MS the immune attack can quiet down for weeks, months, or even years, letting symptoms ease or disappear; neurologists try to extend these quiet spells—called remission or “no evidence of disease activity” (NEDA)—with early use of disease-modifying drugs, healthy habits, and regular MRI checks. Remission isn’t a cure because slow nerve damage can still smolder, and it is uncommon in secondary- or primary-progressive MS, so sticking with treatment and follow-up appointments remains vital even when you feel well.

      What is the most common cause of death in MS patients?

      Death certificates show that the commonest “underlying” cause of death in people with MS is the disease itself (ICD-10 G35), accounting for roughly half of all deaths; this label usually stands for advanced disability complicated by infections and breathing problems. Cardiovascular disease and cancer trail well behind (each about one-tenth to one-fifth of deaths), so focusing on preventing aspiration, treating infections quickly, staying mobile, and managing heart-health risks offers the biggest leverage for living longer with MS.

      What not to do if you have MS?

      Think of “don’ts” in three buckets: 1) anything that drives inflammation (smoking, heavy drinking, high-salt or highly processed, high-saturated-fat foods); 2) anything that lets the body decondition or overheat (long periods of inactivity, extreme heat without cooling strategies); and 3) anything that interferes with treatment safety (skipping or delaying prescribed medicines, starting high-dose supplements or live vaccines, or stopping disease-modifying therapy without your neurologist’s okay). Steering clear of these pitfalls, while staying active, eating mostly whole foods, and working closely with your MS team, gives the best chance of slowing attacks and disability.

      What is the new test for MS?

      Doctors now have a spinal-fluid test called the “kappa free light-chain (KFLC) index,” which measures tiny antibody pieces instead of looking for oligoclonal bands. In several large studies it identified multiple sclerosis with about 90–95 % sensitivity and 85–90 % specificity, is run on an automated machine (so it’s faster, cheaper, and less subjective), and many centers are beginning to add it to the standard work-up, although it still requires a lumbar puncture and currently complements rather than fully replaces oligoclonal-band testing.

      Is MS a disability?

      Multiple sclerosis is recognized by disability laws in the U.S., U.K., Canada and many other countries, but you are considered “disabled” only if your specific symptoms—such as fatigue, vision loss, or mobility problems—limit everyday tasks or steady work despite treatment. Because MS progression varies widely (some stay mild for decades while roughly one-third need a cane within 15 years), keep detailed medical records and talk with your neurologist, employer, or a benefits adviser early to document limitations, request job accommodations, or file for disability support if needed.

      How many brain lesions are normal with MS?

      There isn’t a “normal” or required lesion count for multiple sclerosis: some people have none on the first MRI, others show a handful, and studies put the typical range at roughly 5–15 lesions. What matters more to doctors is where the spots are and whether new ones appear over time—four or more lesions, especially in key areas like around the ventricles, can raise concern for future disability, but prognosis depends on the pattern and evolution rather than any single number.

      Has anyone reversed MS?

      So far no treatment has reliably “turned MS off” for everyone, but limited reversal of disability can occur. Many patients regain some or all lost function after a relapse, and small clinical trials of autologous stem-cell transplantation show that about 50-70 % of carefully selected, highly active cases improve their disability scores for several years, though the procedure carries notable risks and is not yet routine care. Current disease-modifying drugs aim to prevent new damage, and research into remyelination medicines is underway, but a guaranteed, widely available way to reverse MS does not yet exist.

      Are MS cases on the rise?

      Yes, the head-count of people living with multiple sclerosis is climbing worldwide—up roughly one-third since 1990—largely because people are being diagnosed earlier and living longer with the disease. New cases per year (incidence) have risen only modestly and unevenly, suggesting that improved detection and better treatments, rather than an explosive growth in risk, account for most of the increase, though lifestyle factors such as low vitamin D, obesity, smoking and EBV infection may also play a smaller role.

      Does MS run in families?

      MS can cluster in families, but it is not passed down in a simple all-or-nothing way: the lifetime chance is about 1 in 300 for anyone, rises to roughly 1 in 30 (≈2–3 %) if you have a parent, child, or sibling with MS, and even identical twins match only about 1 in 4 times—proof that genes are only part of the story. Because most relatives never develop the disease, routine genetic testing isn’t recommended; instead, general health steps that may lower risk (adequate vitamin D, avoiding smoking, healthy weight) are sensible for everyone.

      What is the progressive treatment for MS?

      Treatment for progressive MS has two parts. First, disease-modifying drugs such as ocrelizumab (for primary-progressive) and siponimod or, in some cases, cladribine/rituximab (for active secondary-progressive) can slow further disability when started early under an MS specialist’s care. Second, an ongoing personalised plan—physiotherapy and exercise, medicines for spasticity, pain, bladder or fatigue, plus good sleep, diet, vaccination and prompt treatment of infections—helps control day-to-day symptoms and prevents complications, with regular reviews to adjust both pieces as the condition evolves.